LAUSR

To the Editor: We congratulate Witteveen et al (1) of the Molecular Diagnosis and Risk Stratification of Sepsis consortium for their prospective investigation of systemic inflammatory marker patterns among patients with ICU-acquired weakness (AW) in a recent issue of Critical Care Medicine. This well-designed observational study provides a detailed description of a morbid condition that is becoming more and more common. Almost 50% of critically ill patients with at least 48 hours of mechanical ventilation demonstrated evidence of ICU-AW. Although the enrollment strategy successfully identified a relatively heterogeneous population of critically ill patients, there was a common theme that was unrelated to inclusion criteria: 79% of the total study population and 88% of all patients with ICU-AW had sepsis, defined as presence of systemic inflammatory response syndrome plus antibiotic administration. Patients with ICU-AW also had a median ICU length of stay of 16 days, versus only 7 days among patients without ICU-AW, and had higher Sequential Organ Failure Assessment (SOFA) scores. These findings suggest that the ICU-AW cohort was composed of patients who would have succumbed to multiple organ failure in previous eras; in modern ICUs, these patients survive and develop chronic critical illness (CCI) (2) and the persistent inflammation-immunosuppression and catabolism syndrome (PICS) (3). ICU-AW may be a manifestation of these conditions. Although the study by Witteveen et al (1) was not designed to assess whether the subjects had persistent inflammation juxtaposed with simultaneous suppression of adaptive immunity or whether patients with ICU-AW were also experiencing protein catabolism, these scenarios seem likely based on previous findings (3). Although plasma elevations in interleukin (IL)-6, IL-8, IL-10, and fractalkine generally occurred prior to measurement of muscle strength testing in both groups, elevated concentration of these cytokines may be best understood as representative of persistent inflammation rather than its cause. To understand what drives persistent inflammation and elevation of inflammatory cytokines on a mechanistic level, we must also consider noninfectious conditions like extended ventilatory support, immobility, exposure of extracellular matrix by injured tissues, and chronic low-grade organ injury (SOFA) driving the release of endogenous danger signals (4). Persistent inflammation in critically ill patients is generally associated with protein wasting, abnormal hematopoiesis, and immune suppression, often leading to secondary infections and/or viral reactivation. Although not reported here, one could reasonably expect that patients with extended ICU stays and prolonged mechanical ventilation would likely have increased frequency of secondary infections (5). These infectious events would only serve to exacerbate inflammation, immune suppression, and protein wasting. Witteveen et al (1) are to be congratulated for making this important contribution to our understanding of ICU-AW. Importantly, ICU-AW needs to be considered in the context of a holistic approach to an understanding of CCI. PICS was originally proposed as a hypothesis that could be experimentally tested in preclinical and clinical settings (3). As evidence accumulates for the existence of a common underlying pathophysiology for many of the conditions that adversely affect critically ill patients, we hope that the scientific community will continue to work together in elucidating this pathway and to promote the development of novel management strategies and therapies targeting this pathway. Dr. Loftus received support from a postgraduate training grant (T32 GM-008721) in burns, trauma, and perioperative injury from the National Institute of General Medical Sciences (NIGMS); his institution received funding from the National Institute of General Medical Sciences/National Institutes of Health (NIH); and he received support for article research from the NIH. Drs. Moore and Moldawer received support from P50 GM111152–01 awarded by the NIGMS, and their institutions received funding from the National Institute of General Medical Sciences/NIH. Dr. Moore received support for article research from the NIH.